Alterations in serotonin metabolism in the irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 2, 2016, Pages 272-282

  Thijssen, A Y ^a,b   Mujagic, Z ^a,b   Jonkers, D M A E ^a,b   Ludidi, S ^a,b   Keszthelyi, D ^a,b   Hesselink, M A ^a,b   Clemens, C H M ^c   Conchillo, J M ^a   Kruimel, J W ^a   Masclee, A A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Alrijne Zorggroep ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; HUMAN; HUMAN TISSUE; IRRITABLE COLON; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SEROTONIN METABOLISM; THROMBOCYTE POOR PLASMA; DIET RESTRICTION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; FASTING; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUALITY OF LIFE; SEROTONIN; YOUNG ADULT;

EID: 84955183378     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13459     Document Type: Article

References (63)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Hungin AP, Whorwell PJ, Tack J, Mearin F,. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50.
3. Olden KW,. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122: 1701-14.
4. Camilleri M, Heading RC, Thompson WG,. Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1407-30.
5. El-Salhy M,. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-63. doi: 10.3748/wjg.v18.i37.5151
6. Drossman DA, Camilleri M, Mayer EA, Whitehead WE,. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
7. Kim DY, Camilleri M,. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-709.
8. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA,. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43.
9. Berger M, Gray JA, Roth BL,. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355-66. doi: 10.1146/annurev.med.60.042307.110802
10. Cremon C, Carini G, Wang B, et al,. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011; 106: 1290-8. doi: 10.1038/ajg.2011.86
11. Gershon MD, Tack J,. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414. doi: 10.1053/j.gastro.2006.11.002
12. Gershon MD,. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 3-14. doi: 10.1111/j.1365-2036.2004.02180.x
13. Matricon J, Meleine M, Gelot A, et al,. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-31. doi: 10.1111/apt.12080
14. Mawe GM, Coates MD, Moses PL,. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1067-76. doi: 10.1111/j.1365-2036.2006.02858.x
15. Tack J, Janssen P, Wouters M, Boeckxstaens G,. Targeting serotonin synthesis to treat irritable bowel syndrome. Gastroenterology 2011; 141: 420-2. doi: 10.1053/j.gastro.2011.06.024
16. Erspamer V, Testini A,. Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 1959; 11: 618-23.
17. Nikisch G, Mathe AA, Czernik A, et al,. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 2004; 24: 283-90.
18. Park SY, Park MH, Yoon KW, et al,. Plasma 5-hydroxytryptamine concentration and its correlation with psychopathology in patients with irritable bowel syndrome. Gut Liv 2009; 3: 26-30. doi: 10.5009/gnl.2009.3.1.26
19. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ,. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-70.
20. Bearcroft CP, Perrett D, Farthing MJ,. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 42-6.
21. Dunlop SP, Coleman NS, Blackshaw E, et al,. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
22. Kilkens TO, Honig A, Fekkes D, Brummer RJ,. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls. Aliment Pharmacol Ther 2005; 22: 865-74. doi: 10.1111/j.1365-2036.2005.02660.x
23. Bradford K, Shih W, Videlock EJ, et al,. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012; 10: 385-90 e381-383.doi: 10.1016/j.cgh.2011.12.018
24. Sykes MA, Blanchard EB, Lackner J, Keefer L, Krasner S,. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med 2003; 26: 361-72.
25. Kim JJ,. Serotonin, stress, and conditioning. Biol Psychiatry 2008; 63: 819-20. doi: 10.1016/j.biopsych.2008.03.001
26. Stasi C, Bellini M, Costa F, et al,. Neuroendocrine markers and psychological features in patients with irritable bowel syndrome. Int J Colorectal Dis 2013; 28: 1203-8. doi: 10.1007/s00384-013-1646-4
27. Keszthelyi D, Troost FJ, Jonkers DM, Kruimel JW, Leue C, Masclee AA,. Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state. J Psychosom Res 2013; 74: 501-4. doi: 10.1016/j.jpsychores.2013.01.008
28. Faresjo A, Grodzinsky E, Johansson S, Wallander MA, Faresjo T, Timpka T,. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm 2008; 14: 870-7.
29. Hirowatari Y, Hara K, Kamihata H, Iwasaka T, Takahashi H,. High-performance liquid chromatographic method with column-switching and post-column reaction for determination of serotonin levels in platelet-poor plasma. Clin Biochem 2004; 37: 191-7. doi: 10.1016/j.clinbiochem.2003.11.009
30. Thijssen AY, Jonkers DM, Leue C, et al,. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol 2010; 44: e236-41. doi: 10.1097/MCG.0b013e3181eed5d8
31. van der Zee KI SR,. Het meten van de algemene gezonsheidstoestand met de RAND-36, een handleiding. [Assessment of General Health Status with the RAND-36; Guidebook]. Groningen: Noordelijk Centrum voor Gezondheidsvraagstukken Rijksuniversiteit Groningen, 1993.
32. Creed F, Ratcliffe J, Fernandez L, et al,. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134: 860-8.
33. Farivar SS, Cunningham WE, Hays RD,. Correlated physical and mental health scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes 2007; 5: 54.
34. Bjelland I, Dahl AA, Haug TT, Neckelmann D,. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69-77.
35. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
36. Nixon GF, Steffeck JC,. Reliability of the State-Trait Anxiety Inventory. Psycho-logical Reports. 1977; 40: 357-8.
37. Houghton LA, Brown H, Atkinson W, et al,. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status. Aliment Pharmacol Ther 2009; 30: 919-29. doi: 10.1111/j.1365-2036.2009.04121.x
38. McLean PG, Borman RA, Lee K,. 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 2007; 30: 9-13. doi: 10.1016/j.tins.2006.11.002
39. Fowler JS, Logan J, Wang GJ, et al,. Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci USA 2003; 100: 11600-5. doi: 10.1073/pnas.1833106100
40. Fowler JS, Volkow ND, Wang GJ, et al,. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996; 93: 14065-9.
41. Foley S, Garsed K, Singh G, et al,. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011; 140: 1434-43 e1431. doi: 10.1053/j.gastro.2011.01.052
42. Kerckhoffs AP, ter Linde JJ, Akkermans LM, Samsom M,. SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1053-60. doi: 10.1152/ajpgi.00153.2011
43. El-Salhy M, Wendelbo I, Gundersen D,. Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep 2013; 8: 451-5. doi: 10.3892/mmr.2013.1525
44. Coates MD, Mahoney CR, Linden DR, et al,. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-64.
45. Shekhar C, Monaghan PJ, Morris J, et al,. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013; 145: 749-57. quiz e713-744. doi: 10.1053/j.gastro.2013.07.014
46. Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, Del Tacca M,. The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol Med 2008; 14: 295-304. doi: 10.1016/j.molmed.2008.05.001
47. Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, Price LH,. Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 2003; 28: 339-47. doi: 10.1038/sj.npp.1300025
48. Barton DA, Esler MD, Dawood T, et al,. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry 2008; 65: 38-46. doi: 10.1001/archgenpsychiatry.2007.11
49. Honig G, Jongsma ME, van der Hart MC, Tecott LH,. Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. PLoS ONE 2009; 4: e6797. doi: 10.1371/journal.pone.0006797
50. Levy RL, Olden KW, Naliboff BD, et al,. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1447-58.
51. Kruimel J, Leue C, Winkens B, et al,. Integrated medical-psychiatric outpatient care in functional gastrointestinal disorders improves outcome: a pilot study. Eur J Gastro Hepatol 2015. doi: 10.1097/MEG.0000000000000335
52. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR,. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-60.
53. Cooke CE, Mehra IV,. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994; 51: 762-71.
54. Gunput MD,. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 70-6.
55. Tack J, Fried M, Houghton LA, Spicak J, Fisher G,. Systematic review: the efficacy of treatments for irritable bowel syndrome-a European perspective. Aliment Pharmacol Ther 2006; 24: 183-205.
56. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S,. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004; 54: 495-502.
57. Lin S, Mooney PD, Kurien M, Aziz I, Leeds JS, Sanders DS,. Prevalence, investigational pathways and diagnostic outcomes in differing irritable bowel syndrome subtypes. Eur J Gastro Hepatol 2014; 26: 1176-80. doi: 10.1097/MEG.0000000000000171
58. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P,. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 2014; 39: 312-21. doi: 10.1111/apt.12573
59. Patel P, Bercik P, Morgan DG, et al,. Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. Aliment Pharmacol Ther 2015; 41: 449-58. doi: 10.1111/apt.13074
60. de Rey Castro NG, Miller V, Carruthers HR, Whorwell PJ,. Irritable bowel syndrome: a comparison of subtypes. J Gastroenterol Hepatol 2015; 30: 279-85. doi: 10.1111/jgh.12704
61. Franke L, Schmidtmann M, Riedl A, van der Voort I, Uebelhack R, Monnikes H,. Serotonin transporter activity and serotonin concentration in platelets of patients with irritable bowel syndrome: effect of gender. J Gastroenterol 2010; 45: 389-98. doi: 10.1007/s00535-009-0167-y
62. Brand T, Anderson GM,. The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. Clin Chem 2011; 57: 1376-86. doi: 10.1373/clinchem.2011.163824
63. Keszthelyi D, Troost FJ, Jonkers DM, et al,. Does acute tryptophan depletion affect peripheral serotonin metabolism in the intestine? Am J Clin Nutr 2012; 95: 603-8. doi: 10.3945/ajcn.111.028589